Cancer Network
Spotlight
Acute Lymphoblastic LeukemiaAround the PracticeASCO Genitourinary Cancers SymposiumHER2-Positive Breast CancerNon-Small Cell Lung Cancer (NSCLC)Prostate Cancer
Clinical
View MoreBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
All NewsNP/PAPractice ManagementTechnology
Media
Around the PracticeClinical ConsultEnduring WebinarsExpert InterviewsK-CastMedical World NewsPodcastsReadout 360Tumor Board Series
Conferences
Publications
About Oncology JournalOncology Journal
Events
Live EventsVirtual Events
CME/CE
Resources
Image IQPollsQuizzesSlideshowsSponsoredToolkits
Subscribe
eNewsletterPrint Subscription

  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • Acute Lymphoblastic Leukemia
  • Around the Practice
  • ASCO Genitourinary Cancers Symposium
  • HER2-Positive Breast Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Prostate Cancer
ClinicalSee All >
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.

Gene Signature ID’s Breast Cancer Patients Who Could Skip Chemotherapy

July 10, 2017
Dave Levitan
Dave Levitan

A 70-gene expression score can identify women with indolent breast cancer at “ultralow” risk, according to a new study. Women with such a score have extremely low risk of disease-specific mortality over 20 years without systemic therapy.

A 70-gene expression score can identify women with indolent breast cancer at “ultralow” risk, according to a new study. Women with such a score have extremely low risk of disease-specific mortality over 20 years without systemic therapy.

Breast cancer screening has increased detection of cancers. “The bulk of the increase has been in early-stage tumors (stage 0, I), suggesting that screening contributes disproportionately to the diagnosis of biologically more indolent forms of breast cancer,” wrote study authors led by Laura J. Esserman, MD, MBA, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. “While screening is associated with a relative mortality reduction of 20%, it has increased the diagnosis of low-risk lesions and contributes to overtreatment.”

The new study was a secondary analysis of the STO-3 trial, which included postmenopausal women with clinically detected node-negative breast cancer treated with mastectomy or lumpectomy and radiation; they were then treated with either two years of tamoxifen or no systemic therapy. This analysis included 652 women with results from the MammaPrint 70-gene expression assay; results were published online ahead of print in JAMA Oncology.

Of the full cohort, 377 women (58%) were MammaPrint low risk, 275 women (42%) were high risk, and 98 women (15%) were ultralow risk. The ultralow-risk patients had better breast cancer–specific survival than both the low- and high-risk patients (log rank P < .001).

In ultralow-risk patients who received tamoxifen, there were no breast cancer–specific deaths at 15 years, and breast cancer–specific survival at 20 years was 97%. Patients without any systemic therapy had a 97% breast cancer–specific survival rate at 10 years, and 94% at 20 years.

A multivariate analysis found that patients with high-risk MammaPrint scores had a long-term risk of breast cancer–specific death of 4.73 (95% CI, 1.38–16.22) compared with ultralow-risk tumors. Those with low-risk-but not ultralow-risk-tumors also had an increased risk of breast cancer–specific death, of 4.54 (95% CI, 1.40–14.80), compared with ultralow-risk tumors.

“The ultralow-risk threshold of the 70-gene signature, in postmenopausal women with node-negative tumors 3 cm or smaller, reliably identifies women with minimal risk of death from breast cancer out to 20 years in the absence of any systemic therapy and negligible risk of death with 2 or more years of tamoxifen therapy alone,” the authors concluded.

They noted that the frequency of ultralow-risk cancers in a screened population of postmenopausal women is likely in the range of 25%. “Such tools, if integrated into screening, treatment, and trials, can prevent inadvertent overtreatment and enable excellent outcomes with less toxic effects.”

Related Content:

Breast Cancer
FDA Issues Response Letter for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer
FDA Issues Response Letter for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer
Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures
Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures
Black Women With Node-Negative Breast Cancer More Likely to Have High-Risk Recurrence Scores Than Non-Hispanic White Women
Black Women With Node-Negative Breast Cancer More Likely to Have High-Risk Recurrence Scores Than Non-Hispanic White Women